Human Platelet Lysate (HPL) is a non-animal derived cell culture growth supplement obtained from blood platelets after freezing and thawing. HPL contains abundant factors and cytokines necessary for cell growth and proliferation. Platelet lysate can be used as a source of growth for replacing bovine serum in cell culture medium. HPL is a rich supplement that maximizes mesenchymal stem cell (MSC) derived from human blood and enhances its genetic stability by removing the risk of xenogeneic immune reactions and viral pathogens.
It has been used in numerous phase I clinical trials worldwide. HPL serves as an alternative to Fetal Bovine Serum (FBS) in cell and tissue culture. For example, growth kinetics for primary kidney cells maintained in 5% HPL containing medium were found to be comparable to those of cultures grown in medium supplemented with 10% FBS.
Obtain Report Details @https://www.transparencymarketresearch.com/human-platelet-lysate-market.html
Human platelet lysaten is derived from human donor platelets and the donor unit is pooled in large batch size, which are then further processed and manufactured to produce a consistent product. Heparin (Porcine), an anticoagulant derived from the porcine intestine, is used in the preparation of human platelet lysate to inhibit coagulation. The USFDA is moving toward adopting European guidelines requiring that bovine materials be removed from culturing media for any therapeutic product containing cultured cells, thus making HPL an attractive alternative to the production and manufacturing processes, which is likely to fuel the demand for human platelet lysate during the forecast period.
Replacing bovine serum with HPL allows for expansion and clinical grade production of functional mesenchymal stromal cells by removing the risk of xenogeneic immune reactions and transmission of bovine prion and viral pathogens. There are various methods to prepare human platelet lysate, such as, it can be prepared by repeating freeze and thaw cycles, direct platelet activation by signification, calcium chloride, or detergent. Manufacturers are focusing on pooling as many as 50+ donors for the production of a single human platelet lysate batch with new techniques, offering a window to propel the growth of the HPL market.
Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=46329
The global human platelet lysate market can be segmented on the basis of product type, application, end-user, and geography. Based on product type, the global human platelet lysate market can be divided into human platelet lysate with heparin and heparin-free human platelet lysate.
Based on application, the global human platelet lysate market can be classified into research and clinical applications. In terms of end-user, the market can be categorized into biopharmaceutical companies, contract research organizations, academic & research institutes, pharmaceutical companies, and others. Increased application of human platelet lysate in cell culture due to its advantages over fetal bovine serum is anticipated to drive the global human platelet lysate market during the forecast period. Rising acceptance due to less batch-to-batch variability in human platelet lysate is also fueling the growth of the market. Furthermore, increase in opposition for animal blood derived products is indirectly promoting the use of human platelet lysate in cell culture.
Fetal bovine serum is the mostly used for cell culture; human platelet lysate is considered potential substitute for fetal bovine serum due to easy availability and less variability in results. These factors are expected to drive the global human platelet lysate market during the forecast period. However, increase in risk of transmission of communicable infectious diseases and the high cost of cell biology research are anticipated to limit the growth of the market during the forecast period.
Geographically, the global human platelet lysate market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for the leading share of the market, in terms of revenue, followed by Europe. Factors contributing to the dominant position of North America in the human platelet lysate market are high consumption of human platelet lysate for cell culture as a substitute of fetal bovine serum. The human platelet lysate market in Asia Pacific is expected to expand at a significant CAGR in the near future. High growth rate of the market in the region can be ascribed to increase in research activities and rise in the number of contract research organizations in the region.
Key players operating in the global human platelet lysate market are Mill Creek Life Sciences, LLC, Merck & Co., Inc, STEMCELL Technologies Inc, AventaCell BioMedical, Compass Biomedical, Inc, Macopharma SA, Trinova Biochem GmbH, PL BioScience GmbH, and Cook Regentec, among others.